- Home
- UAN vs IMTX Comparison
UAN vs IMTX Comparison
Compare UAN & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAN | IMTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UAN | IMTX |
|---|---|---|
| Price | $130.00 | $8.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 21.5K | ★ 580.7K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 12.06 | N/A |
| Revenue | ★ $606,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | $10.97 | ★ N/A |
| Revenue Growth | ★ 15.36 | N/A |
| 52 Week Low | $89.20 | $6.86 |
| 52 Week High | $139.50 | $12.41 |
Technical Indicators
Market Signals| Indicator | UAN | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 42.05 |
| Support Level | $117.14 | $8.37 |
| Resistance Level | $138.77 | $10.51 |
| Average True Range (ATR) | 3.07 | 0.35 |
| MACD | -0.35 | -0.06 |
| Stochastic Oscillator | 38.23 | 25.57 |
Price Performance
Historical ComparisonAbout UAN CVR Partners LP
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.